cancer-therapy

Documents about cancer-therapy

• Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant#283041ClinicalTrials.gov
• From basic mechanisms to clinical research: photodynamic therapy applications in head and neck malignancies and vascular anomalies#781878Spiral
• Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial#167768Griffith Research Online
• Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR#374451HAL (France)
• Lignes directrices de l’OMS pour le dépistage et le traitement des lésions précancéreuses pour la prévention du cancer du col de l’utérus#638109WHO IRIS
• Towards individualized treatment planning for PSMA-targeted radioligand therapy of advanced prostate cancer: from in silico determination of the relative biological effectiveness to image-based red bone marrow dosimetry / Mikhail Rumiantcev ; Betreuer: Guido Böning#661773Deutsche Nationalbibliothek
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies#256861ClinicalTrials.gov
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer#184800ClinicalTrials.gov
• Synergistic Sensitization of Pancreatic Cancer Cells by Nanosecond Pulsed Electric Fields and Cold Atmospheric Plasma Via Amplifying ROS and Apoptotic Signaling#449650ODU Digital Commons
• Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers#179022Lund University Publications
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies#234411ClinicalTrials.gov
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer#314345ClinicalTrials.gov
• Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer#346989ClinicalTrials.gov
• Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy#148777ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of D#164844Unpaywall
• How to manage renal masses in kidney transplant recipients? A collaborative review by the EAU-YAU kidney transplantation and renal cancer working groups#301242IRIS
• In situ generated biopolymers towards a reverse prodrug therapy for hard-to-treat cancers#456129University of Nottingham Repository
• Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery#67864ClinicalTrials.gov
• Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer#344476HAL (France)
• Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma#307462ClinicalTrials.gov
• A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation#435749ClinicalTrials.gov
• Image 3_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367121Figshare
• Image 4_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367122Figshare
• Image 1_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367123Figshare
• Image 2_Case Report: Short-term response to mesenchymal epithelial transition inhibitor/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management.tif#367124Figshare
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer#683089ClinicalTrials.gov
• Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail#180391ClinicalTrials.gov
• Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma#201758ClinicalTrials.gov
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy#279528ClinicalTrials.gov
• A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.#143556ClinicalTrials.gov
• Molecular Engineering of Asymmetric Cyanines with Hybridized Local and Charge-Transfer Characteristics for NIR-II Imaging-Guided Type I/II Photodynamic Therapy#391556Figshare
• Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy#619956eScholarship
• PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes#320317IRIS
• Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner#432900ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology#161134Zenodo (CERN)
• Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France)#226862HAL (France)
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome#18710ClinicalTrials.gov
• RNA-seq dataset: GB1275, a small-molecule agonist of cd11b, combined with drug-loaded oncolytic bacteria for pancreatic cancer therapy.#359847Figshare
• Effects of photobiomodulation on oral mucositis, oral pain, xerostomia, salivary flow rate, and quality of life in patients with head and neck cancer: A systematic review and meta-analysis#197611Research Online
• Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant#407722ClinicalTrials.gov
• Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma#442108ClinicalTrials.gov
• Oncologic outcomes in a contemporary "PROTEUS-like" cohort of high-risk prostate cancer treated with radical prostatectomy without neoadjuvant hormonal therapy / Can Aydogdu, Benso John, Clara Seizer, Frederik Kolligs, Iason Papadopoulos, Alexander Buchner, Elena K. Berg, Jozefina Casuscelli, Julie Steinestel, Roman Mayr, Matthias Heck, Christian G. Stief, Thilo Westhofen#783976Deutsche Nationalbibliothek
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer#279514ClinicalTrials.gov
• Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma#325313ClinicalTrials.gov
• ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma#172304ClinicalTrials.gov
• PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy#141010ClinicalTrials.gov
• Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma#435734ClinicalTrials.gov
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma#290974ClinicalTrials.gov
• Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation#467591ClinicalTrials.gov
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma#249606ClinicalTrials.gov